Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT01113476
Phase
PHASE1
Status
Completed

Conditions

  • Advanced Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nab-paclitaxel — DRUG
    Starting dose of 50 mg/m\^2 on Day 1, 8 + 15 every 28 days (+/- 2 days)
  • Bevacizumab — DRUG
    Starting dose of 5 mg/m\^2 on Day 1 + 15 every 28 days (+/- 2 days)
  • Gemcitabine — DRUG
    1000 mg/kg Day 1, 8 + 15 every 28 days (+/- 2 days)

Study Details

The goal of this clinical research study is to find the highest tolerable dose of the combination of Abraxane (nab-paclitaxel), Gemzar (gemcitabine), and Avastin (bevacizumab) that can be given to patients with advanced cancer. The safety of this drug combination will also be studied.

Key Dates

First listed
Apr 30, 2010
Start date
Apr 27, 2010
Status verified
Aug 2022
Primary completion
Aug 12, 2022
Completion
Aug 12, 2022

Study Design

Enrollment
176 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Nab-paclitaxel, Gemcitabine + Bevacizumab
    Starting doses of Nab-paclitaxel 50 mg/m\^2, Bevacizumab 5 mg/kg + fixed dose of Gemcitabine 1000 mg/m\^2

Primary Outcome Measure

Maximum Tolerated Dose (MTD) of Gemcitabine, Nab-Paclitaxel and Bevacizumab [ Time Frame: With each 28 day cycle ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of Texas MD Anderson Cancer CenterHoustonTexas77030-

Find similar trials in Houston, TX

By research site
University of Texas MD Anderson Cancer Center· Houston, TX

Related Studies